Use of SAS® Graph Template Language and HIGHLOWPLOT to Create a Next-Generation Sequencing Multi-Gene Panel Grid John Bennett Statistical Programmer Genomic.

Slides:



Advertisements
Similar presentations
Understanding Genome-Wide Profiling of Cancer
Advertisements

Taking the Leap - Using ODS Statistical Graphics for Data Visualization Wei Cheng, Isis Pharmaceuticals, Inc.
Excel Graphing Tutorial Lauren Ottaviano Fall 2012.
Graphing With Excel 2010 University of Michigan – Dearborn Science Learning Center Based on a presentation by James Golen Revised by Annette Sieg…
Driving the Transition to Individualized Cancer Treatment by Addressing Critical Questions 1 Do I need surgery? chemotherapy? radiation? INVASIVE BREAST.
Graphical Reporting of Clinical Trial Data with SAS ODS Graphics
Validation of a 12-Gene Colon Cancer Recurrence Score ® in Stage II Colon Cancer Patients from CALGB 9581 A.P. Venook 1, D. Niedzwiecki 2, M. Lopatin 3,
TS02 SAS GTL - Injecting New Life into Graphs
Genomic Health, Inc. Yuko Soneoka, Ph.D., J.D. Senior Corporate Counsel, IP Director of Intellectual Property January 31, 2013.
SMART/FHIR Genomic Resources
Dr. Andreas Scherer President and CEO Golden Helix, Inc. Twitter: andreasscherer Utilizing cancer sequencing in the clinic: Best.
Introduction to SAS/Graph 9.2 Ken Barz Colorado Prevention Center 22Oct2009 Ken Barz Colorado Prevention Center.
Creating Graphs in PowerPoint Step 1 Open a new PowerPoint Document.
Prostate Cancer Management: A Guide for Patients and Caregivers
Kaitlyn McConville, Rho ®, Inc. Kristen Much, Rho ®, Inc. PharmaSUG 2015 Paper #DV02.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
1 Bioinformatics Tools for Genotyping Frances Tong Dr. Garry Larson, Ph.D City of Hope Department of Molecular Medicine Southern California Bioinformatics.
The world leader in serving science Andy Felton Ph.D. Vice President Marketing & Product Management Clinical Sequencing Division Personalized Medicine.
CtDNA NGS testing identified a high-level MET amplification (copy number of 53.6 in circulation) (Figure 1A). The test was repeated on a second tube of.
Anna Buder Institute of Cancer Research Department of Medicine I Medical University of Vienna Liquid Biopsies Analysis of circulating cell-free tumor-DNA.
PD-L1 expression patterns in the metastatic tumors to the lung: a comparative study with the primary non-small cell lung cancer Zoran Gatalica1*, Jude.
Big Data in Genomics, Diagnostics, and Precision Medicine
Hereditary Cancer Predisposition: Updates in Genetic Testing
Data and Hartwig Medical Foundation
Excel Lesson 8 Working with Charts
GraDe-SVM: Graph-Diffused Classification for the Analysis of Somatic Mutations in Cancer Morteza H.Chalabi, Fabio Vandin Hello.
SIMS 247 Lecture 7 Simultaneous Multiple Views
Synthetic Circulating Cell-free DNA as Quality Control Materials for Somatic Mutation Detection in Liquid Biopsy for Cancer R. Zhang, R. Peng, Z. Li, P.
Fig 1A. Patient enrollment flow chart
Excel Part 4 Working with Charts and Graphics
Jeopardy Testing 1, 2, 3 She Has The Cancer Radiation or Chemo?
Christopher S. Lathan, M. D. , M. S. , M. P. H
Techniques for measuring minimal residual disease in leukemia
Excel Part 4 Working with Charts and Graphics
Unità Clinica di Diagnostica Istopatologica e Molecolare
Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms
Content and Labeling of Tests Marketed as Clinical “Whole-Exome Sequencing” Perspectives from a cancer genetics clinician and clinical lab director Allen.
Regulatory Industry Statistics Workshop 2018
Single-Color Digital PCR Provides High-Performance Detection of Cancer Mutations from Circulating DNA  Christina Wood-Bouwens, Billy T. Lau, Christine.
Monitoring EGFR mutation status in Non-small cell lung cancer (NSCLC) patients using circulating Tumour DNA (ctDNA). Matthew Smith Molecular Pathology.
Heatmaps of the gene mutation distributions in oncogene‐signaling blocks for six representative cancer types. Heatmaps of the gene mutation distributions.
Donavan T. Cheng, Talia N. Mitchell, Ahmet Zehir, Ronak H
Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.
Serum vs FNA:.
Mainstreaming Genomic Medicine post 100,000 Genomes Project
Click Headings Above to View Content
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Closing Cancer Cases Not Under Active Care
Genomic Testing: When and Why
PROSTATE CANCER CIRCULATING BIOMARKER CONSENSUS STATEMENT QUESTIONS
Cancer WGS Analytical Pipeline Validation
Volume 152, Issue 1, Pages (January 2019)
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
Mary Alikian ICHT Cancer validation update
Excel Lesson 8 Working with Charts
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Excel Part 4 Working with Charts and Graphics
Esteller, New England Journal of Medicine, 2008
Detection of somatic mutations in plasma allows for non-invasive real time therapy response monitoring of lung cancer patients José Carlos Machado.
Frequent alterations identified and potential actionability.
FGFR3 mutation analysis of a selection of urine samples from patients included with an FGFR3-mutant (MT) tumor. FGFR3 mutation analysis of a selection.
The NCI Genomic Data Commons as an engine for precision medicine
Prevalence of germline T790M.
Global mutational landscape of the 170 lung adenocarcinoma patients (discovery cohort). Global mutational landscape of the 170 lung adenocarcinoma patients.
Mutational Analysis of Ionizing Radiation Induced Neoplasms
Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for.
A, study design for measuring the feasibility, concordance, and accuracy of a plasma-based cfDNA sequencing test compared with biopsy-based sequencing.
DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.
Hege G. Russnes, et al: Breast Cancer Molecular Stratification From Intrinsic Subtypes to Integrative Clusters. The American Journal of Pathology. Vol.
ADME Study PK SDTM/ADAM And Graph
Presentation transcript:

Use of SAS® Graph Template Language and HIGHLOWPLOT to Create a Next-Generation Sequencing Multi-Gene Panel Grid John Bennett Statistical Programmer Genomic Health, Inc. Redwood City, California

Genomic Health, Inc. (GHI) ® A global provider of genomic-based diagnostic tests These tests provide personalized biological information that helps patients and their physicians select the most appropriate treatment Oncotype DX Breast Recurrence Score® test launched in 2004 Additional tests launched for colon, DCIS, and prostate cancer The portfolio of tests continues to expand with additional liquid- and tissue-based tests

Multi-gene NGS panel GHI developed a liquid biopsy next-generation sequencing (NGS) mutation panel for 4 cancer types, including non-small cell lung cancer (NSCLC) Using a plasma (blood) sample, this panel identifies specific genomic variants in 17 genes Clinically actionable variants were reported to physicians and patients (e.g., EGFR, ALK, KRAS) Deliverable: a graphic that displays the actionable variants for all patients

Example of multi-gene panel results Lee HY, et al. J Korean Med Sci. 2017;32(3):415-420.

HIGHLOWPLOT: 2 types TYPE = line TYPE = bar \

Use Graph Template Language (GTL) and HIGHLOWPLOT with type=bar to create variant grid TEMPLATE procedure used to define the structure of the graph proc template; define statgraph variantgrid; begingraph; layout lattice / border=false; layout overlay / yaxisopts=(display=(tickvalues) reverse=true tickvalueattrs=(style=italic) linearopts=(tickvaluelist=(0 1 2 3 4 5 6 7 8 9 10 11 12))) xaxisopts=(label='Patients' display=(label) labelattrs=(size=9)); highlowplot y=rownum high=eval(Patient+0.5) low=eval(Patient-0.5) / type=bar; endlayout; endgraph; end; run; proc sgrender data=grid template=variantgrid; where VariantType1 < 99; Patient is numbered consecutively starting at 1 HIGHLOWPLOT creates a bar chart where HIGH and LOW defined as patient ID ± 0.5. rownum contains the genes, also numbered consecutively starting at 1. SGRENDER procedure creates the graph using the template defined in the TEMPLATE procedure

HIGHLOWPLOT without additional elements

Attribute maps for additional color proc template; define statgraph variantgrid; begingraph; discreteattrmap name='vt'; value 'SNV' / fillattrs=(color=cx00B0F0) lineattrs=(color=cxFFFFFF); value 'Indel' / fillattrs=(color=cxFF0000) lineattrs=(color=cxFFFFFF); value 'Translocation' / fillattrs=(color=cxFFD700) lineattrs=(color=cxFFFFFF); value 'CNV' / fillattrs=(color=cx87BF62) lineattrs=(color=cxFFFFFF); value 'Squamous' / fillattrs=(color=cx000080) lineattrs=(color=cxFFFFFF); value 'Non-squamous' / fillattrs=(color=cx808080) lineattrs=(color=cxFFFFFF); value 'None' / fillattrs=(color=cxDEDDED) lineattrs=(color=cxFFFFFF); enddiscreteattrmap; discreteattrvar attrvar=vartyp1 var=VariantType1 attrmap='vt'; layout lattice / border=false; layout overlay / yaxisopts=(display=(tickvalues) reverse=true tickvalueattrs=(style=italic) linearopts=(tickvaluelist=(0 1 2 [...] 11 12))) xaxisopts=(label='Patients' display=(label) labelattrs=(size=9)); highlowplot y=rownum high=eval(Patient+.5) low=eval(Patient-.5) / type=bar group=vartyp1; endlayout; endgraph; end; run;   proc sgrender data=grid template=variantgrid; VariantType1 contains formatted values for each variant type GROUP by the ATTRVAR vartyp1

HIGHLOWPLOT with color added for NSCLC subtype and variant type

Sorting and additional graphical elements Sort the data to create groups, potentially revealing relationships between genes and variant types Add LEGENDITEM statements legenditem type=marker name="nonsq_legend" / markerattrs=(color=cx808080 symbol=squarefilled size=11) label="Non-squamous"; legenditem type=marker name="sq_legend" / markerattrs=(color=cx000080 symbol=squarefilled size=11) label="Squamous"; legenditem type=marker name="snv_legend" / markerattrs=(color=cx00B0F0 symbol=squarefilled size=11) label="SNV"; [etc]

Sorting and additional graphical elements Some patients had two variants on a single gene Add a second attribute map for the marker type and fill color discreteattrmap name='vt2'; value 'CNV' / markerattrs=(color=cx87BF62 size=7 symbol=squarefilled); value 'Translocation' / markerattrs=(color=cxFFD700 size=7 symbol=squarefilled); value '.' / markerattrs=(size=0); enddiscreteattrmap; discreteattrvar attrvar=vartyp2 var=VariantType2 attrmap='vt2'; Add two SCATTERPLOTS to lay over the HIGHLOWPLOT scatterplot y=eval(rownum+.13) x=Patient / group=vartyp2; scatterplot y=eval(rownum+.32) x=Patient / group=vartyp2; Additional SCATTERPLOT for germline variants scatterplot y=germline x=Patient / markerattrs=(symbol=asterisk size=4);

Sorting and additional graphical elements To place the legend to the right of the graph, update the original LAYOUT LATTICE statement to include 2 columns layout lattice / columns=2 columnweights=(0.8 0.2) border=false; Add an additional LAYOUT LATTICE for the legend with 2 rows layout lattice / rows=2 rowweights=(0.1 0.9) border=false; layout overlay; discretelegend 'nonsq_legend' 'sq_legend' / down=2 border=false halign=left valign=center; endlayout; discretelegend 'snv_legend' 'indel_legend' 'trans_legend' 'cnv_legend' 'gl_legend’ / down=5 border=false halign=left valign=top;

Final graph

Conclusion The HIGHLOWPLOT statement, in combination with other GTL graphical elements, is an effective means to create a grid of variants HIGHLOWPLOT could potentially be used anytime a heat map or grid is required for a graph Sorting the results so that the data are logically grouped on the graph can reveal interesting patterns that may lead to further investigation

Contact Information Name: John Bennett Company: Genomic Health, Inc. City/State: Redwood City, CA Phone: 650-569-5681 Email: jbennett@genomichealth.com http://www.genomichealth.com/ https://www.oncotypeiq.com/en-US/